Fundamental Analysis of EVOLUS INC(NASDAQ:EOLS) stock

Fundamental Rating

EOLS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of EOLS have multiple concerns. EOLS shows excellent growth, but is valued quite expensive already.

Quickly go to:

1. Profitability

1.1 Basic Checks

EOLS had negative earnings in the past year.

In the past year EOLS has reported a negative cash flow from operations.

In the past 5 years EOLS always reported negative net income.

In the past 5 years EOLS always reported negative operating cash flow.

1.2 Ratios

EOLS's Return On Assets of -32.64% is in line compared to the rest of the industry. EOLS outperforms 53.33% of its industry peers.

		Industry Rank	Sector Rank
ROA	-32.64%
ROE	N/A
ROIC	N/A

ROA(3y)-30.87%

ROA(5y)-41.6%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a decent Gross Margin value of 69.54%, EOLS is doing good in the industry, outperforming 72.82% of the companies in the same industry.

In the last couple of years the Gross Margin of EOLS has remained more or less at the same level.

EOLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	69.54%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.94%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

EOLS does not have a ROIC to compare to the WACC, probably because it is not profitable.

EOLS has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, EOLS has more shares outstanding

Compared to 1 year ago, EOLS has a worse debt to assets ratio.

2.2 Solvency

EOLS has an Altman-Z score of -1.10. This is a bad value and indicates that EOLS is not financially healthy and even has some risk of bankruptcy.

With a Altman-Z score value of -1.10, EOLS perfoms like the industry average, outperforming 48.72% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-1.1

ROIC/WACCN/A

WACC9.27%

2.3 Liquidity

A Current Ratio of 2.33 indicates that EOLS has no problem at all paying its short term obligations.

EOLS's Current ratio of 2.33 is on the low side compared to the rest of the industry. EOLS is outperformed by 61.03% of its industry peers.

A Quick Ratio of 2.10 indicates that EOLS has no problem at all paying its short term obligations.

EOLS has a Quick ratio (2.10) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	2.33
Quick Ratio	2.1

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

EOLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.61%, which is quite impressive.

Looking at the last year, EOLS shows a very strong growth in Revenue. The Revenue has grown by 35.98%.

Measured over the past years, EOLS shows a very strong growth in Revenue. The Revenue has been growing by 52.93% on average per year.

EPS 1Y (TTM)32.61%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q14.29%

Revenue 1Y (TTM)35.98%

Revenue growth 3Y52.93%

Revenue growth 5YN/A

Revenue growth Q2Q39.75%

3.2 Future

The Earnings Per Share is expected to grow by 47.35% on average over the next years. This is a very strong growth

Based on estimates for the next years, EOLS will show a very strong growth in Revenue. The Revenue will grow by 27.36% on average per year.

EPS Next Y42.83%

EPS Next 2Y50.71%

EPS Next 3Y52.97%

EPS Next 5Y47.35%

Revenue Next Year29.5%

Revenue Next 2Y31.02%

Revenue Next 3Y30.32%

Revenue Next 5Y27.36%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

EOLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year EOLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as EOLS's earnings are expected to grow with 52.97% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y50.71%

EPS Next 3Y52.97%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for EOLS!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

EVOLUS INC

NASDAQ:EOLS (5/7/2024, 1:49:22 PM)

13.46

+0.07 (+0.52%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap826.04M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-32.64%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	69.54%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover1.07

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.33
Quick Ratio	2.1
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)32.61%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y42.83%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)35.98%

Revenue growth 3Y52.93%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

EVOLUS INC (EOLS)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens